Regeneron Pharmaceuticals Inc (REGN)
Receivables turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 13,044,200 | 13,025,200 | 12,601,200 | 12,306,100 | 12,113,500 | 13,654,100 | 14,171,800 | 16,451,800 | 16,014,400 | 13,499,700 | 12,328,800 | 9,147,000 | 8,455,000 | 8,201,600 | 7,974,500 | 7,957,900 | 7,839,900 | 7,598,200 | 7,213,600 | 6,889,000 |
Receivables | US$ in thousands | 5,667,300 | 5,584,500 | 5,121,300 | 5,118,600 | 5,328,700 | 5,548,300 | 5,161,400 | 4,839,000 | 6,036,500 | 5,452,000 | 6,998,600 | 4,173,000 | 3,111,500 | 3,553,300 | 2,380,200 | 2,531,400 | 2,360,600 | 2,373,100 | 2,172,200 | 2,016,000 |
Receivables turnover | 2.30 | 2.33 | 2.46 | 2.40 | 2.27 | 2.46 | 2.75 | 3.40 | 2.65 | 2.48 | 1.76 | 2.19 | 2.72 | 2.31 | 3.35 | 3.14 | 3.32 | 3.20 | 3.32 | 3.42 |
December 31, 2023 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $13,044,200K ÷ $5,667,300K
= 2.30
Regeneron Pharmaceuticals, Inc.'s receivables turnover has fluctuated over the past eight quarters, ranging from a low of 2.28 in Q4 2022 to a high of 3.41 in Q1 2022. The average receivables turnover ratio over this period is approximately 2.64.
A lower receivables turnover ratio indicates that the company is taking longer to collect payments from its customers, which could be a potential concern regarding the company's liquidity and its ability to manage its receivables effectively. Conversely, a higher ratio suggests that Regeneron Pharmaceuticals is collecting payments more efficiently.
The declining trend in the receivables turnover ratio from Q1 2022 to Q4 2023 may raise questions about the company's credit policies, customer payment behaviors, or potential issues with accounts receivable management. It is important for analysts to further investigate the reasons behind these fluctuations to assess the overall effectiveness of Regeneron Pharmaceuticals' receivables management strategy.
Peer comparison
Dec 31, 2023
See also:
Regeneron Pharmaceuticals Inc Receivables Turnover (Quarterly Data)